Wall Street brokerages forecast that Evogene Ltd. (NASDAQ:EVGN) will report earnings of ($0.18) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Evogene’s earnings. Evogene posted earnings per share of ($0.26) in the same quarter last year, which suggests a positive year-over-year growth rate of 30.8%. The company is expected to report its next quarterly earnings report on Monday, February 26th.
On average, analysts expect that Evogene will report full-year earnings of ($0.74) per share for the current year. For the next year, analysts anticipate that the business will post earnings of ($0.44) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Evogene.
Evogene (NASDAQ:EVGN) last issued its quarterly earnings results on Wednesday, November 22nd. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Evogene had a negative net margin of 555.45% and a negative return on equity of 26.17%.
Shares of Evogene (NASDAQ:EVGN) traded down $0.13 during midday trading on Wednesday, hitting $3.66. The stock had a trading volume of 496 shares, compared to its average volume of 11,847. Evogene has a 1 year low of $2.66 and a 1 year high of $5.84. The stock has a market cap of $98.11, a PE ratio of -4.41 and a beta of 0.55.
A hedge fund recently raised its stake in Evogene stock. Vanguard Group Inc. grew its position in shares of Evogene Ltd. (NASDAQ:EVGN) by 4.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 436,225 shares of the biotechnology company’s stock after buying an additional 17,391 shares during the period. Vanguard Group Inc. owned 1.70% of Evogene worth $2,443,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 30.94% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Anticipate Evogene Ltd. (EVGN) to Post -$0.18 Earnings Per Share” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/31/zacks-brokerages-anticipate-evogene-ltd-evgn-to-post-0-18-earnings-per-share.html.
Evogene Company Profile
Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd.
Get a free copy of the Zacks research report on Evogene (EVGN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.